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Exercise Tests in
Heart Failure Patients
Is Simple Better?*
Stanley A. Rubin, MD
Los Angeles, California
The most direct, and in a sense the most important, problem
which our conscious knowledge of nature should enable us to
solve is the anticipation of future events, so that we may arrange
our present affairs in accordance with such anticipation.
Heinrich Hertz (1)
My wife exits my wardrobe closet in despair of ever seeing
me discard some old, infrequently worn, and out-of-fashion
clothing. She then recites to me an aphorism from a media
maven of homemaking: “Simplify.” She wants me to get rid
of the obsolete, focus on essential needs, and thereby
simplify my life. Can we apply this bit of domestic wisdom
to the choice of selecting an exercise test for the “anticipa-
tion of future events” in heart failure patients?
In a clinical research article in this issue of the Journal,
Forman et al. (2) suggest that, perhaps, we can. This is 1 of
See page 2653
myriad substudies from Heart Failure: A Controlled Trial
Investigating Outcomes of Exercise Training (HF-
ACTION), a randomized multicenter trial designed to test
the effect of exercise training on major adverse events in over
2,000 patients with moderately severe heart failure (3,4). In
this substudy, the authors assessed the value of baseline
clinical data as well as that of 2 baseline exercise tests (1 simple,
1 complex) for predicting the mortality and morbidity (primary
outcome) and mortality (secondary outcome) of patients en-
rolled in the study. The 6-minute walk (6MW) test served as
the simple test, whereas the cardiopulmonary exercise (CPX)
test served as the complex test. The former assesses functional
capacity from the distance a patient walks over a measured
course during a 6-minute period (5). The latter assesses
unctional capacity as well as cardiopulmonary performance,
ncluding peak oxygen consumption and anaerobic threshold,
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contents of this paper to disclose.uring exercise on a treadmill or cycle ergometer with collec-
ion and analysis of expired gas (6).
From what is known about the quality of data from these
xercise tests, we would anticipate that the baseline complex
PX test performed better at predicting adverse events than
he baseline simple 6MW test. Surprisingly, the authors
ound that the 6MW test performed about as well as the
PX test in estimating the major study outcomes at an
verage follow-up of 2.5 years (2). What are the takeaway
essages from this study?
bsence of a strong effect limits application of this
tudy. As in most research, the study value rises and falls on
he basis of its methods, its data analysis, its results and
nterpretation, and, from that point, to application. With
espect to the methods and data analysis, Journal readers will
recognize that the statistical test used in this kind of study is
some type of correlation analysis between a variable obtained at
baseline and the frequency of the endpoint of morbidity and
mortality. In this study (2), the authors used the C statistic. Its
range of values for a reasonable model is from 0.5 to 1.0.
When a model provides no information, C  0.5.
When the authors used clinical variables alone (as indi-
cated at the bottom of Table 5 in the paper) for predicting
the primary study endpoint, the value of the C statistic was
0.60 (2). By adding the 6MW test data, the value of the C
statistic barely increased to 0.62. The CPX fared little
better, with the C statistic value increasing to only 0.63.
Therefore, although the simple 6MW test performed about
as well as the more complex CPX test in predicting
outcome, neither added very much to the prediction of the
primary endpoint beyond the clinical variables. In response
to a suggestion from manuscript reviewers (disclosure: I did
not review this manuscript), the authors were quite forth-
coming in sections of the paper, when they stated, “[the data
from the exercise studies added] only modest prognostic
discrimination to models that included important demo-
graphic and clinical covariates. . .” (2).
The demographic and clinical variables might have per-
formed better (i.e., had greater predictive value) if they
included the biomarker B-type natriuretic peptide, the left
ventricular ejection fraction, and the New York Heart
Association class. Indeed, all of these variables were ob-
tained at baseline. I was surprised to find an HF-ACTION
substudy that analyzed the correlation between B-type
natriuretic peptide and performance of the 2 exercise tests
(7). It is not clear why these data were not included in the
analysis of the current study. So, where does that leave us
with respect to exercise testing in heart failure research and
clinical management?
Potential benefit in the design of future heart failure
research studies. One or the other of these exercise
tests—or both, as in the HF-ACTION study—is routinely
included in trials of drugs and devices in chronic heart
failure studies, because it is recognized that baseline func-
tional capacity is part of characterizing enrolled patients.
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and at the end of the study, change in functional capacity in
response to treatment or management strategy is an impor-
tant result. The 6MW test is technically less demanding and
less expensive than a CPX test. Therefore, unless a heart
failure study requires collection of a variable only available
from the CPX test, such as oxygen consumption or anaer-
obic threshold, the 6MW test may suffice for the purpose of
measuring functional capacity in future studies. The simple
6MW test could be of particular value in studies that include
patients who are older, frail, physically deconditioned, or
have advanced heart failure symptoms.
Exercise testing is useful in heart failure management.
Attributing patient symptoms of fatigue and dyspnea to
heart failure in the presence of, for example, musculoskeletal
disorders, pulmonary disorders, or chronic diseases, or even
the level of physical conditioning or volition of a patient, is
not always readily resolved by history, physical examination,
and initial laboratory tests. Cardiology clinical guidelines
state, in part, “. . . Symptoms of both systolic and diastolic
heart failure may first manifest as dyspnea or fatigue during
physical activity. Therefore, it is appropriate to assess the
functional capacity of patients with confirmed or suspected
heart failure to determine whether, in fact, such impairment
exists. . .” (6). For this purpose, the 6MW test is practical
and simple. In select patients, the value of the test may be
increased by the use of rhythm and oximetry monitoring.
The conduct of the test should follow published guidelines
(5). Although the test is very safe for patients, both
resuscitative equipment and qualified personnel must be
on-hand and organized so as to manage a rare untoward
event (8).
At the other end of complexity, the CPX test, with
measurement of peak oxygen consumption and other vari-
ables, is a class IIa guideline recommendation for identifi-
cation of candidates for cardiac transplantation, determina-
tion of disability, and assistance in the formulation of an
exercise prescription. Its role in the general management of
patients with heart failure has not been defined (9).
The 6MW test is valuable in the assessment of other
cardiopulmonary disorders. Of particular value in deter-
mining functional capacity and response to therapy in
pulmonary arterial hypertension (PAH), the 6MW test is
the only exercise endpoint accepted by the U.S. Food and
Drug Administration and the European Agency for the
Evaluation of Medicinal Products for use in studies evalu-
ating treatment effects (10). In patients with PAH, serial
determinations of functional class and exercise capacity
assessed by using the 6MW test provide benchmarks for
disease severity, response to therapy, and progression (11).
Conclusions. So, is simple better? If the question is which
exercise test—the simple 6MW or the complex CPX
test—to include as part of a heart failure research study,
then the answer is a qualified “yes” in favor of the 6MW
test. In addition, the 6MW test is a useful adjunct for the pclinician who is trying to determine the cause of a patient’s
dyspnea or fatigue, and is also likely useful in charting the
progress of therapy or the clinical course of some patients
who have heart failure or PAH. However, predicting
adverse events in heart failure (Hertz’s admonition about
“anticipation of future events”) largely rests on clinical and
demographic variables. Forman et al. (2) demonstrate that
prediction of prognosis was little enhanced by adding the
results of either the 6MW or the CPX test.
As for my personal problem of convincing my wife to
leave my closet contents alone, I doubt that she’ll relent
from her view of “simplify.”
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